BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.

    Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck.

    Shown are Western blot analysis of Wnt5a expression in HDPCs treated with TNF-a (n=3–4). The gene expression level was normalized to GAPDH (n = 3–6). HDPCs were preincubated with pyrrolidinedithiocarbamic acid (PDTC, an NF-κB inhibitor), BAY11-7082 (an NF-κB inhibitor), SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor), or U0126 (an ERK inhibitor) before treatment with TNF-a.

    J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck.

  • The effect of vaspin on TNF α -induced THP-1 cell adhesion to HAECS measured staining with VibrantDiO® Cell-Labeling Solution. The level of THP-1 cell adhesion to HAECs was measured at 4 hr after treatment with 25 -100 ng/mL vaspin in the presence or absence of 10 ng/mL TNF α . BAY11-7082 (10 uM, S2913, Selleckchem, USA), an inhibitor of NF- κ B, was used as a positive control.

    Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa Mnm3SpVv[3Srb36gRZN{[Xl? NVm4eVJFOTEEoN88US=> NYf2bpJvOS53IHi= M2[xOYFjd2yrc3jld{BDWEFiaX7keYNm\CC3cDDy[Yd2dGG2aX;uJI9nKE[QIHHu[EBOVVBvOdMg NXzrfVZpOjV5OUe0N|c>
SiHa  M{HndWZ2dmO2aX;uJGF{e2G7 Mn7WNVDDqM7:TR?= MkCwNU42KGh? Mlu4ZYJwdGm|aHXzJGJRSSCrbnT1Z4VlKHWyIILl[5Vt[XSrb36gc4YhTk5iYX7kJG1OWC17wrC= M2\L[|I2Pzl5NEO3
ARPE-19 NF72XY5HfW6ldHnvckBCe3OjeR?= NFnnWIEyKM7:TR?= M16zfFAvPSCq NIr2[lR{fXCycnXzd4V{KFSJLXnu[JVk\WUEoFnMMVjDqHC{b33veIVzKGGldHn2ZZRqd25? MmjiNlU2QTNyMkm=
HCT116 MYrGeY5kfGmxbjDBd5NigQ>? MWm1JO69VQ>? Mo[4NkBp MVvEUXNQ MXrheJRmdnWjdHXzJJNqdHmvYYLpck1qdmS3Y3XkJIRwf26{ZXf1cIF1cW:wIH;mJIN6[2yrbjDENS=> MWOyOVQ4QTd{Mx?=
HMECs Ml22SpVv[3Srb36gRZN{[Xl? Mn21OeKh|ryP MWGyJIg> MUThZo9tcXOqZYOgWG5HNc7zLXnu[JVk\WRiVlPBUU0yKGW6cILld5Nqd28EoB?= MonaNlUyQTNzMU[=
A549  NIjWfGdHfW6ldHnvckBCe3OjeR?= Mn;rNVDjiIoEtV2= MVqxNkBp NEfpfIN{fXCycnXzd4V{KES4bD2zJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCyNkW= MlHuNlUyPTZ6MEC=
RAW 264.7 M1f5WmZ2dmO2aX;uJGF{e2G7 MY[1xsDPxE1? M2XqTFEhcA>? MUTpcohq[mm2czDUUmYu|rFiYX7kJGlNNTF{IIC0NEBxem:mdXP0bY9v NFPZU2gzPTBzOUW2Oy=>
macrophages Mn63SpVv[3Srb36gRZN{[Xl? M2fEOVUhyrWP M{XtXVMhcA>? NUj2RYpDeGG{dHnhcIx6KGKub3Prd{B[WE[VLXnu[JVk\WRiZYjwdoV{e2mxbjDv[kBqVk:VIHHu[EBEV1hvMtMg NHv0RXEzPDl4N{i5PC=>
HUVECs NFfBNVhHfW6ldHnvckBCe3OjeR?= M4\2UlMuOzBizszN MkjHNUBp Ml63doVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDtbXIuOTR4YTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVHYVphZOjR6NkO5OlU>
HeLa  NGHrNXZHfW6ldHnvckBCe3OjeR?= MoroOeKh|ryP Mk\5NlQhcA>? M2jIXGROW09? M3;pb5Jm\HWlZYOgeIhmKGGldHn2bZR6KG:oIGTOSk3PuSCycn;tc5RmesLi M2j4dlI1PjV5N{iz
A549 M3\E[mZ2dmO2aX;uJGF{e2G7 NXnLUJRCOTBizszN NYXHW3BvOeLCiXi= NXGy[lFPcW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJBpd3OyaH:tTe67Ss7zIHnuJHBCOTB|LXnu[oVkfGWmIHP1cJR2emW|wrC= MmTaNlQ3OTJ2OEi=
HUVEC M4nROmZ2dmO2aX;uJGF{e2G7 NWX0[Y9lOjBiwsXN NIfTWG0xNjViaB?= MWnEUXNQ NY\zUphleHKndnXueJMhfGinIHnu[JVkfGmxbjDv[kBGSU1iZYjwdoV{e2mxbh?= MXGyOFU2OTJyOR?=
A549RT-eto NFH1SGdCeG:ydH;zbZMhSXO|YYm= MnfHNVDDqM7:TR?= MlfJNlQhcA>? MknkSG1UVw>? MVfhZ4NmdGW{YYTld{BHTVKRLX3l[IlifGWmIHHwc5B1d3Orcx?= MX:yOFU{PTB6Mx?=
THP-1  MmDySpVv[3Srb36gRZN{[Xl? MontNE4yNzIEoN88US=> MnXKNE42KGh? NF\CUlZi[nKxZ3H0[ZMhXE6ILd8xJJNm[3KndHnvckBieyC5ZXzsJIF{KHSqZTDpcoNz\WG|ZXSgd4VkemW2aX;uJI9nKEmOLU[gZY5lKEmOLUJOti=> MXGyOFM4QDV|Nh?=
SKCXCR2  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX0e3kzKML3TR?= MUC0PEBp MY\k[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJJNq\26rZnnjZY51dHl? M3XEd|I1Ozd4N{S3
SKCXCR2  NVnnN|A3TnWwY4Tpc44hSXO|YYm= NEPEfIUzKML3TR?= Mm\WOFghcA>? NYK4cIRn[myxY3vzJJRp\SCFWFPMNU1qdmS3Y3XkJINmdGxiaX72ZZNqd25? MoWzNlQ{PzZ5NEe=
OVCXCR2 NHHuWYZHfW6ldHnvckBCe3OjeR?= M2Du[lIhyrWP NXjxWW14PDhiaB?= M{H1d4Jtd2OtczD0bIUhS1iFTEGtbY5lfWOnZDDj[YxtKGmwdnHzbY9v NVnnblVUOjR|N{[3OFc>
DSCs  MnPxSpVv[3Srb36gRZN{[Xl? MmfJNk42KM7:TR?= M1jjWFAvPSCq MlPEdoV3\XK|ZYOgeIhmKGWwaHHuZ4Vu\W62IH;mJGNEVDJxQ1PSNkBmgHC{ZYPzbY9vKG:oIFTTR5MhcW6mdXPl[EBjgSCLTD2zNy=> M4PCUlI1OzR2MkSw
WPs MXLGeY5kfGmxbjDBd5NigQ>? M4WxNVI2KM7:TR?= Ml3HOUBucW5? NGLPNG1{fXCycnXzd4V{KEGWUDDhcoQhfleIIIPlZ5JmfGmxbh?= NHT0dpIzPDN|MUKwOy=>
A549RT-eto MVTBdI9xfG:|aYOgRZN{[Xl? NXnFW4VbOTEEoN88US=> M2PhOVI1KGh? MWPhZ4NmdGW{YYTld{BHOTRiZYj0doFkfC2vZXTpZZRm\CCjcH;weI9{cXNiY3;tZolv\WRidILlZZRu\W62IIfpeIghTjF2 MnL6NlQzOjB5MkW=
A549RT-eto NV[1NXdMTnWwY4Tpc44hSXO|YYm= MUSxNOKh|ryP NEHkd2gzPCCq Mn;D[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDOSk3PwkJiYX7kJHAu\3EEoB?= NH;5dlMzPDJ{MEeyOS=>
FaDu NHTDZ2dHfW6ldHnvckBCe3OjeR?= Mny4NkBp NILLb3pqdmirYnn0d{BxPjViZYjwdoV{e2mxbjDhcoQh[myxY3vzJHRPTs7zLXnu[JVk\WRiVGfJV3Qh\XiycnXzd4lwdg>? NFXBe|MzPDJ{ME[yNi=>
IVD  M161VGZ2dmO2aX;uJGF{e2G7 MXKxNOKh|ryP NXfEXWx6OyCm NH23O2hz\X[ncoPld{BVVkZvzsJihLNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjD0bIUh\Gm|YzDtZZRzcXhibXHjdo9ud2ynY4Xs[ZMh[WepcnXjZY4h[W6mIHPvcIxi\2WwIFnJ MmTwNlQyPzZ6MEi=
IVD  MkTsSpVv[3Srb36gRZN{[Xl? NV;L[WNlOTEEoN88US=> NH;IOVE{KGR? NHO1O2Ni[nKxZ3H0[ZMhXE6ILd8x5qCUcW6mdXPl[EB2eC2{ZXf1cIF1cW:wIH;mJGFFSU2WUz20JIFv\CCDRFHNWHMuPcLi NWPycJdIOjRzN{[4NFg>
iNKT MlXxSpVv[3Srb36gRZN{[Xl? Mn\JNVAwOTByIN88US=> MmnMNE42KGh? MlP0bY5pcWKrdIOgeIhmKGmwZIXjeIlwdiCxZjDBNmFTKG2UTlGgZY5lKG:2aHXyJIZi[3Sxch?= NYXrNYJHOjRzMkS0OVM>
PC-3 MWTGeY5kfGmxbjDBd5NigQ>? MXiyMlUwPS9zMDFOwG0> M2nHfVAvPSCq MYnicI9kc3NiSVfGMWlKNWmwZIXj[YQhW1SVIH3SUmEh\XiycnXzd4lwdsLi M{LucVI1ODV3NUKw
THP-1  M{PXXGZ2dmO2aX;uJGF{e2G7 MYGxNOKh|ryP MknqNeKhcA>? M3XmNYFjd2yrc3jld{B1cGViZX\m[YN1KG:oIILIV3AzPyCxbjDTVk1CKG2UTlG= NHjkenUzOzl|OUO5PC=>
A549 MYDGeY5kfGmxbjDBd5NigQ>? M3n3eVHDqM7:TR?= MYm0PEBp NEHsWHhmdmijbnPld{B1cGVidYCtdoVofWyjdHnvckBw\iCLzsrCJIFv\CC|dXLz[ZF2\W62IHTlZ5Jm[XOnIHnuJGJigCCneIDy[ZN{cW:wIHnu[JVk\WRiYomgZ49u[mmwZXSgd5RqdXWuYYTpc44> NIHH[IczOzlyMEC4NC=>
A549 NHvJPYZCeG:ydH;zbZMhSXO|YYm= M2TxbFHDqM7:TR?= NXP5[nlyPDhiaB?= NFvHeWZz\WS3Y3XzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgZ49u[mmwZXSgd5RqdXWuYYTpc44> NV3JOZdqOjN7MECwPFA>
NCI-N87 NYn6N4txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjHNW8yOC9{MD:zNEDPxE1? MkDtOk8zPCCq NVjCRoRke3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7 NHz5dJUzOzh2NkW0OS=>
AGS M13IWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrOcZhZOTBxMkCvN|Ah|ryP NFnCWW83NzJ2IHi= NEPiR41{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MYGyN|g1PjV2NR?=
MGC80-3 NVrFbGt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnQ[poyOC9{MD:zNEDPxE1? M1vRZ|YwOjRiaB?= NXOwWXc3e3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7 MlmxNlM5PDZ3NEW=
HGC-27  MmCySpVv[3Srb36gRZN{[Xl? MoD0O{42NzF3L{OwJO69VQ>? MnrjOkBp M2nXTIlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKGGwZDD1dE1z\We3bHH0bY9vKG:oIFpOvmLPuQ>? MnX3NlM5PDZ3NEW=
MGC80-3 NH;qSopHfW6ldHnvckBCe3OjeR?= NUHmbGhkPy53L{G1M|MxKM7:TR?= M3f5SVYhcA>? NVTkT3hocW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25iYX7kJJVxNXKnZ4XsZZRqd25ib3[gTe67Ss7z MX6yN|g1PjV2NR?=
HGC-27  Mmm3RZBweHSxc3nzJGF{e2G7 M2nGOVcvPS9zNT:zNEDPxE1? NGHDXHk3KGh? MlXkbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmS5NlM5PDZ3NEW=
HBE  M2Pye2Z2dmO2aX;uJGF{e2G7 MkXjNVDPxE1? NUn4NnZjO2h? NUfobGxS[WKxbHnzbIV{KHSqZTDpcoNz\WG|ZYOgc4YhUUxvNjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhS1OH NIi4fHgzOzh{NEC4PS=>
HepG2 M2XDfGZ2dmO2aX;uJGF{e2G7 M2P4flAvOy9zL{Og{txO MXS0PEBp MkDQdoVlfWOnczDJUFYucW6mdXPl[EBRV05zIHX4dJJme3Orb36= MUeyN|c6OTh|Mx?=
THP-1 NXzhdZBqTnWwY4Tpc44hSXO|YYm= MojIOUDDvU1? MkjkNUBp NYfuZpZmTE2VTx?= NHL1bllqdmirYnn0d{BOXEJvaX7keYNm\CCQRt86RkBi[3SrdnH0bY9v MnPuNlM3OzR{MUi=
THP-1  MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr4PIs2KML3TR?= NGXKcIQ1NzhiZB?= M1zIUGROW09? NUizdGRoemWmdXPld{B1cGVidnnhZoltcXS7IH;mJIlvfHKjY3XscJVt[XMEoF3URi=> MXWyN|Y{PDJzOB?=
MDM MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm3bGwzPSEEtV2= Mn3nOE85KGR? Moq0SG1UVw>? M3rlWJJm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK= NGfHZlYzOzZ|NEKxPC=>
AM MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYW1JOK2VQ>? NVOxPZM6PC96IHS= NVrrVWxLTE2VTx?= MXjy[YR2[2W|IITo[UB3cWGkaXzpeJkhd2ZiaX70doFk\WyudXzhduKhVVSE Ml6yNlM3OzR{MUi=
RAW 264  NX[1XW1xTnWwY4Tpc44hSXO|YYm= NF7ZeHExNjJvNTFCuW0> NUXpPXdHOzBxNkCvPVAhdWmw Mn\GbY5pcWKrdIOgeIhmKHCqb4PwbIF1[XOnIHHjeIl3cXS7IH;mJHBVWDGEwrC= MnvFNlM2Pzh|MEK=
HUVEC M4DRSGZ2dmO2aX;uJGF{e2G7 MWexNOKh|ryP NVn4S45GOC53IHi= M3;oNWROW09? NIridYJkd3WwdHXyZYN1\XNidHjlJIxwe3Nib3[gWIlmOiCvUl7B MlHTNlM2PjN4M{K=
HT29 NVuwc|lyTnWwY4Tpc44hSXO|YYm= MXixNE8{OC9zMECg{txO NVHldnA{OSCq NGfqSGVqdmirYnn0[ZMh[m:2aDDUW2VCUy2rbnT1Z4VlKHBzMECgdJJw[2W|c3nu[y=> NYHJ[HdROjN3MkexOVQ>
HT29 M33zdWZ2dmO2aX;uJGF{e2G7 M1n4RlExNzNyL{GwNEDPxE1? MoPZNUBp NWXhXnBocW6qaXLpeJMhXE6ILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKGGwZDDk[Ydz[WSjdHnvckBw\iCLzsrC{tE> NYnSTXNmOjN3MkexOVQ>
MM.1S M4HZZmFxd3C2b4Ppd{BCe3OjeR?= Ml\KN|AhyrWP MnrZN{Bp MkTWbY5lfWOnczDNUUBk\WyuIHTlZZRpKGmwdn;seoV{KG6nY4Lvd4l{ M3[xOVI{PTJ5MUW0
KMS-12-BM NVrqe5ZYSXCxcITvd4l{KEG|c3H5 MY[zNEDDvU1? M1vFSVMhcA>? MkLibY5lfWOnczDNUUBk\WyuIHTlZZRpKGmwdn;seoV{KG6nY4Lvd4l{ NUnqN2VDOjN3MkexOVQ>
BAFs NW[zdFNwTnWwY4Tpc44hSXO|YYm= MVOwMlUwOcLizszN NVLoWYttOjRiaB?= M{XUWolvcGmkaYTzJHRPTs7zL1TFXEBqdmS3Y3XkJGN[WDF7QUJCpJRz[W6|Y4LpdJR{ NXzxPFdyOjN2OEW0OVc>
SP6.5 NFLJVZBHfW6ldHnvckBCe3OjeR?= M3H2[|Uh|ryP NUjsfVdkOiCq NETOSGJl\WO{ZXHz[ZPDqHS{YX7zcI9k[XSrb36gc4YheDZ3IHnuJJRp\SCwdXPs[ZV{yqB? MXGyN|Q1OzB6Nh?=
VUP NHrze5lHfW6ldHnvckBCe3OjeR?= NXv0VVdoPSEQvF2= MVWyJIg> MYPk[YNz\WG|ZYRCpJRz[W6|bH;jZZRqd25ib3[gdFY2KGmwIITo[UBvfWOuZYXzxsA> MY[yN|Q1OzB6Nh?=
OCM1 NFTVV|hHfW6ldHnvckBCe3OjeR?= NVe5ToRmPSEQvF2= NHXsSXYzKGh? MXrk[YNz\WG|ZYRCpJRz[W6|bH;jZZRqd25ib3[gdFY2KGmwIITo[UBvfWOuZYXzxsA> NF7VfVMzOzR2M{C4Oi=>
OM431 M332SGZ2dmO2aX;uJGF{e2G7 M{PJfFUh|ryP NF24SWwzKGh? NX\J[IJx\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8Li MljTNlM1PDNyOE[=
SP6.5 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH5WJozNjVvMkCg{txO M3;ZeFI1KGkEoB?= NFfLNXZKSzVyPUWg{txONCCneHjpZol1eyC|dILvcoch[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeJMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYKyN|Q1OzB6Nh?=
VUP NYrocoQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\2PJIzNjVvMkCg{txO M{TOXlI1KGkEoB?= NGmxZoNKSzVyPUWg{txONCCneHjpZol1eyC|dILvcoch[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeJMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3P2ZVI{PDR|MEi2
OCM1 M1;KNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjJWYRHOi53LUKwJO69VQ>? MknFNlQhcMLi MW\JR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Ml24NlM1PDNyOE[=
OM431 NEPlO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnpNk42NTJyIN88US=> MXWyOEBpyqB? NE\WTo5KSzVyPUWg{txONCCneHjpZol1eyC|dILvcoch[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeJMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVrEOVJOOjN2NEOwPFY>
SP6.5 MUPBdI9xfG:|aYOgRZN{[Xl? MVO1JO69VQ>? NI\wb4gzPCCqwrC= NGXVOG1qdmS3Y3XzJIFxd3C2b4Ppd:Kh M4jyflI{PDR|MEi2
VUP MnXsRZBweHSxc3nzJGF{e2G7 MWG1JO69VQ>? Mor0NlQhcMLi MV3pcoR2[2W|IHHwc5B1d3Orc9Mg MlG2NlM1PDNyOE[=
OCM1 MXvBdI9xfG:|aYOgRZN{[Xl? M2\3dlUh|ryP NHrZbYQzPCCqwrC= MULpcoR2[2W|IHHwc5B1d3Orc9Mg MUWyN|Q1OzB6Nh?=
OM431 M1Ltd2Fxd3C2b4Ppd{BCe3OjeR?= M1n0V|Uh|ryP NVfFXmRLOjRiaNMg M4\D[4lv\HWlZYOgZZBweHSxc3nzxsA> MYOyN|Q1OzB6Nh?=
SP6.5 MUPGeY5kfGmxbjDBd5NigQ>? NHfSb2g2KM7:TR?= NYrBfmdZOTJiaB?= MkHydoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? NVrVUW5bOjN2NEOwPFY>
VUP MYnGeY5kfGmxbjDBd5NigQ>? NEDVOlk2KM7:TR?= Ml7pNVIhcA>? MX3y[YR2[2W|IITo[UBucWe{YYTpc47DqA>? MUOyN|Q1OzB6Nh?=
OCM1 MULGeY5kfGmxbjDBd5NigQ>? NEnTeoY2KM7:TR?= NWP2ZmF7OTJiaB?= MlzidoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? NI\nR2MzOzR2M{C4Oi=>
OM431 M2nxb2Z2dmO2aX;uJGF{e2G7 NXqwVGlPPSEQvF2= NGLtNVEyOiCq MmXydoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? M4TUZVI{PDR|MEi2
HBL-1  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWezxsDPxE1? MWCyOE81QC95MjDo M3vXdGROW09? Mon1d4xwf3NiY3XscEBoem:5dHigcY9l\XO2bIm= MUiyN|Q1OTd|MB?=
RAW 264.7 NFzsVGZHfW6ldHnvckBCe3OjeR?= M2L2dlIuOTVizszN NWT2PYtUOSCq MkLWSG1UVw>? M372NpN2eHC{ZYPz[ZMhfGinIHHjeIl3[XSrb36gc4YhUUuNIH\hcYltgSCvZX3i[ZJ{ MYGyN|Q1OTd|MB?=
IL-1R  NFfCVIhHfW6ldHnvckBCe3OjeR?= MlXSNk0yPSEQvF2= Mm[wNUBp NFLOS5JFVVOR NUDaVJVse3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCLS1ug[oFucWy7IH3lcYJmenN? M2DNSVI{PDRzN{Ow
RAW 264.7 NUn0TWlxTnWwY4Tpc44hSXO|YYm= NEfUU3QyPSEQvF2= NIfuNIMyKGh? M4rMZWROW09? NIjGUJJ{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKGGwZDDKUms> NGm0TGMzOzR2MUezNC=>
IL-1R  MWDGeY5kfGmxbjDBd5NigQ>? NILCdoEyPSEQvF2= NH\QfHEyKGh? M3[zcmROW09? NGXpSG5{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKGGwZDDKUms> NEXHW4QzOzR2MUezNC=>
U2OS MVTGeY5kfGmxbjDBd5NigQ>? MkjPNVUh|ryP MXexJIg> M4D6XGROW09? MV\wdoV3\W62czD0bIUhVFCVLTDvdkBKVC1zLYP0bY12dGG2ZXSg[o9zdWG2aX;uJI9nKEt4Mz3wWYIh[2ijaX7zxsA> NF\SNW8zOzR2MUezNC=>
MT‐1  M{ToR2Z2dmO2aX;uJGF{e2G7 M{exWljDqML3bR?= MkPqN{Bp MWrk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCy4pEQV3RCXDNiYX7kJJDjiJB2RVLQNS=> NWLTdGt5OjN{N{i0O|k>
MT‐2  NHnncVBHfW6ldHnvckBCe3OjeR?= MYO4xsDDvW1? MlrKN{Bp M1XSfIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIIFihLBUXEGWMzDhcoQheOLCkETFRnAy NH7LTGgzOzJ5OES3PS=>
MT‐1  MXHGeY5kfGmxbjDBd5NigQ>? NGDDcVE5yqEEtX2= MWGzJIg> MWrk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgdFY2KHO3YoXubZQhd2ZiTldihLDPwkMEoB?= MYqyN|I4QDR5OR?=
MT‐2  NYDjSHNETnWwY4Tpc44hSXO|YYm= M3P5fFjDqML3bR?= NHH1[JE{KGh? M1\5XYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBxPjVic4XieY5qfCCxZjDOSwKBmM78QtMg M1OwNFI{Ojd6NEe5
MCF-7  MoLxSpVv[3Srb36gRZN{[Xl? MWqyMlUuOTVizszN NF3BbHoxNjViaB?= M{fuSmROW09? MmXOZ4F2e2W|IITo[UBoemGmdXHsJIxwe3Nib3[gZ4VtdCCjZHjld4lwdg>? NUXZdlNPOjNyOUOyNlc>
HaCaT  M2TUWGZ2dmO2aX;uJGF{e2G7 NV;DT2g1PS5ywrFOwG0> MUCxxsBpyqB? NY\XNXV7[XS2ZX71ZZRmeyC2aHWgWGNQUC2rbnT1Z4VlKHC{b3T1Z5Rqd25ib3[gTWwuPsLi M1PHblI{ODRzMU[4
A549  NXLrenBLTnWwY4Tpc44hSXO|YYm= MXOxJIg> M1z3VIlvcGmkaYTzJGxVSS2rbnT1Z4VlKFOSLVGgcXJPSSCycn;keYN1cW:wwrDzbYdvcW[rY3HueIx6 M3zsZVI{ODNzMkGz
OA chondrocytes  M3\2SmZ2dmO2aX;uJGF{e2G7 NIXvdocyOCEQvF2= NGj3[poyKGh? NVTUOJgz[myxY3vzJJRp\SCDR1WtRnNCNWmwZIXj[YQh\2WwZT;wdo91\WmwIHX4dJJme3Orb36gc4YhT1KSN{igc5IhS0:[LUKgLJA9OC5yNTm= NIn6U4YzOjl6MkKyPC=>
RAW264.7 M2[3eGZ2dmO2aX;uJGF{e2G7 M2LicVE2KM7:TR?= NXrXVoI1OTVvMUKwJI1qdg>? NVzzU|Fs[myxY3vzJJRp\SCycn;keYN1cW:wIH;mJG5QNCCSR1WyMEBidmRiVF7GMe6y MoXaNlI4PDV3MkO=
RAW264.7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fOb|UuOzBizszN MWGyOEBp NHTmVmlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnLqNlI4PDV3MkO=
HBL6 MmOyRZBweHSxc3nzJGF{e2G7 MXWwMlUwPS9{NTFOwG0> NXL4co43Pi9{NDDo NEPqXGll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZY5lKGynZXHkd{B1dyCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= Mme1NlIxPzR6MkC=
HT29  NYOyfo8zTnWwY4Tpc44hSXO|YYm= MlrINU0yOCEQvF2= MXexNOKhcA>? NXLTd4lucW6lcnXhd4V{KEiRLUGgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u M1\TWlIyPjJyOU[0
Ca9–22 MkDsRZBweHSxc3nzJGF{e2G7 M3;wc|ExyqEQvF5CpC=> NVHudlJZOSCq MXHjc41xdGW2ZXz5JIlvcGmkaYTzJGFNSS2SRGStbY5lfWOnZDDhdI9xfG:|aYO= MlrpNlEyOzh2OEC=
Ca9–22 NH;jeIJHfW6ldHnvckBCe3OjeR?= M{Kz[lExyqEQvF5CpC=> M4jaOFEhcA>? M1jKdINwdXCuZYTlcJkh[WK{b3fheIV{KHSqZTDBUGEuWESWLXnu[JVk\WRiSl7LJIFkfGm4YYTpc44> MWKyNVE{QDR6MB?=
A-549 NGT3W45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELwO|YyOMLizszNxsA> MkXrNlQwPDhiaB?= NWjyRmNLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NFLYUmwzODh4NkC0Ny=>
AP MWHGeY5kfGmxbjDBd5NigQ>? NHTwdWQ2NzFyIN88US=> M2\IRlQ5KGh? MV;kc5dvemWpdXzheIV{KHSqZTDCRWQheHKxdHXpckBt\X[nbDDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWeyNFU6PjZ2NR?=
AQ1 M3;sfGZ2dmO2aX;uJGF{e2G7 MXG1M|ExKM7:TR?= MlfJOFghcA>? NILwSVVld3ewcnXneYxifGW|IITo[UBDSURicILveIVqdiCuZY\lcEBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGLkUoQzODV7Nk[0OS=>
AP M4TXd2Z2dmO2aX;uJGF{e2G7 M33wVVIxKM7:TR?= M{\PfVQwQCCq NXXZVGVy\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NITTZlQzODV7Nk[0OS=>
AQ1 MVTGeY5kfGmxbjDBd5NigQ>? NVTWSZZWOjBizszN MlfiOE85KGh? MoLt[I94dnKnZ4XsZZRmeyC2aHWgRmFFKHC{b4TlbY4hdGW4ZXygZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M37XS|IxPTl4NkS1
THP-1 NXHzWlZITnWwY4Tpc44hSXO|YYm= NXLiXJpWPcLizszNxsA> NE[yPVIxNjViaB?= NGrJ[YdifHSnboXheIV{KHSqZTDMVHMucW6mdXPl[EBxNUoQulNOtUBxem:2ZXnuJIJ6KDd{JR?= MVOyNFMxQTdzOB?=
K562 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P5NVIuOzBizszN NV;tUW82OjRiaB?= M3fvRmlEPTB;ODFOwG0tcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGGybWcyQTZ2NkiwOy=>
Jurket M4jzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\JXZc{Oi1|MDFOwG0> NX\tOYVIOjRiaB?= MoPXTWM2OD15LkGg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX72eGxPOTl4NE[4NFc>
U937 NGnqXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LWUVIuOzBizszN NVnjbm5rOjRiaB?= M1XxXWlEPTB;MUCuOUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFqwNYIyQTZ2NkiwOy=>
PBMC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmyMVMxKM7:TR?= NHO3THgzPCCq NVjn[GE4UUN3ME20NE4zKM7:TTygbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mkj2NVk3PDZ6MEe=
K562 MVzBdI9xfG:|aYOgRZN{[Xl? MVmyMVIxyqEQvF5CpC=> MVGyOEBp NYTWWIppcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIFxd3C2b4Ppdy=> M3[wO|E6PjR4OEC3

... Click to View More Cell Line Experimental Data

Protocol

Cell Research
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 15 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID